Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. ( AKBA ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Nicholas Grund - Senior VP & Chief Commercial Officer Steven Burke - Senior VP and Chief Research & Development Officer Conference Call Participants Andrew Kassin - BTIG, LLC, Research Division Nabeel Nissar - Jefferies LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Peter Keith - Piper Sandler & Co., Research Division Antonio Arce - WestPark Capital, Inc., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Akebia Therapeutics NASDAQ: AKBA reported lower third-quarter revenue and a net loss as sales of its kidney disease drug Auryxia fell and inventory reductions limited revenue growth for its anemia treatment Vafseo, despite a sharp increase in patients receiving the drug.

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025